Company: CMND
Filing Date: 2025-03-13
Form Type: POS AM
Source: 0001213900-25-023708
Chunk: 17

Company: Clearmind Medicine Inc.
Filing Date: 2025-03-13
Form: POS AM
Chunk 17
---
 the                                                                                           
 ability of our pre-clinical and any future clinical trials to demonstrate safety and efficacy 
 of our future product candidates, and other positive results;                                 |

| ● | the                                                                                       
 timing and focus of our future preclinical studies and clinical trials, and the reporting 
 of data from those studies and trials;                                                    |

| ● | the size of the market opportunity                                                                                                  
 for our future product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; |

| ● | the success of competing therapies that are or may 
 become available;                                  |

| ● | the beneficial characteristics, safety, efficacy and                                                                               
 therapeutic effects of our future product candidates, as well as the potential healthcare costs saved through utilizing our future 
 product candidates;                                                                                                                |

| ● | the ability of our future product candidates to address    
 needs not currently addressed by the psychedelic industry; |

| ● | the ability of our future product candidates to address    
 needs not currently addressed by the psychedelic industry; |

| ● | our ability to obtain and maintain regulatory approval 
 of our future product candidates;                      |

| ● | our plans relating to the further development of our                                         
 future product candidates, including additional disease states or indications we may pursue; |

| ● | existing regulations and regulatory developments in 
 the United States and other jurisdictions;          |

| ● | our plans and ability to obtain or protect intellectual                                                                             
 property rights, including extensions of patent terms where available and our ability to avoid infringing the intellectual property 
 rights of others;                                                                                                                   |

| ● | the ability of our management team to oversee our drug 
 research programs;                                     |

| ● | the need to hire additional personnel and our ability 
 to attract and retain such personnel;                 |

| ● | our estimates regarding expenses, future revenue, capital 
 requirements and needs for additional financing;          |

| ● | our dependence on third parties; |

| ● | our ability to compete with other companies who offer                                 
 products that address similar issues that our future product candidates will address; |

| ● | our financial performance; |

| ● | the period over which we estimate                                                                                                     
 our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; |

| ● | our ability to generate revenue and profit margin under      
 our anticipated contracts which is subject to certain risks; |

<div align='center'>6</div>

| ● | difficulties in our partners’ ability to recruit                                                                                
 and retain qualified physicians and other healthcare